NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

自動化和密封細胞調節系統的全球市場:按細胞調節步驟(分離,分離,增殖,回收,填充/完成,冷凍保存,解凍)/按操作規模(臨床前/臨床,實用)

Automated and Closed Cell Therapy Processing Systems Market By Cell Processing Steps (Apheresis, Separation, Expansion, Harvest, Fill Finish, Cryopreservation and Thawing), Scale of Operations (Preclinical / Clinical and Commercial),

出版商 Roots Analysis 商品編碼 996037
出版日期 內容資訊 英文 184 Pages
商品交期: 最快1-2個工作天內
價格
自動化和密封細胞調節系統的全球市場:按細胞調節步驟(分離,分離,增殖,回收,填充/完成,冷凍保存,解凍)/按操作規模(臨床前/臨床,實用) Automated and Closed Cell Therapy Processing Systems Market By Cell Processing Steps (Apheresis, Separation, Expansion, Harvest, Fill Finish, Cryopreservation and Thawing), Scale of Operations (Preclinical / Clinical and Commercial),
出版日期: 2020年10月31日內容資訊: 英文 184 Pages
簡介

諸如細胞療法和基因療法之類的先進治療藥物(ATMP)徹底改變了醫學領域。在過去的20年中,已經批准了30多個ATMP。此外,全球有1000多家公司目前正在進行1,050項臨床試驗,重點是評估細胞療法和基因療法。但是,儘管在這一領域取得了許多進步,但要實現商業成功仍需要解決一些挑戰。例如,當前的細胞療法製造過程是勞動密集型,費時且昂貴的。此外,大多數這些專用治療產品都需要體力勞動,並且通常需要單獨執行(非密封調整),這使得該過程難以擴大規模,並且有很高的污染風險。每個製造商面臨的另一個問題是批次之間的質量差異,即使在製造協議中進行很小的更改也會出現這種差異。結果,細胞療法非常昂貴,每劑花費300,000美元至500,000美元。

專家認為,與細胞療法製造相關的一些挑戰可以通過採用自動化的密封細胞調節系統來解決。這些解決方案已被證明可以使利益相關者在遵守全球法規標準的同時,有效地管理細胞療法藥物生產過程的各個方面。這種系統的其他好處包括減少污染的風險,設備和資源的最佳使用,有限的工藝變化以及穩定的產品質量。另外,使用這種自動化系統可以顯著降低人工成本(在40%至90%的範圍內)。近年來,這些系統的削減成本潛力,以及簡化和簡化複雜的細胞治療過程(從最初的細胞收集到最終的製劑)的能力,在這一領域引起了許多興趣,並有效地吸引了其他人的興趣。鑑於對具有成本效益的個性化藥物的需求不斷增長,再加上自動化和封閉系統的優勢,人們認為這個利基市場已為在可預見的將來實現顯著增長做好了準備。

本報告分析了自動化和閉孔調節系統的全球市場,概述了產品,列出了主要公司/利益相關者,當前業務聯盟的動向和未來可能性以及自動操作,通過引入公式/閉孔調節系統來降低成本, 我們收集了有關總體市場規模趨勢展望(2020-2030),按調整步驟,運營規模,最終用戶和地區以及當前和將來的市場機遇與問題所列出的詳細趨勢的信息。

目錄

第1章簡介

第2章執行摘要

第3章簡介

  • 分析背景
  • 細胞療法
  • 細胞療法藥物的生產
  • 與細胞療法藥物生產相關的主要問題
  • 自動和閉孔調節系統概述
    • 在細胞療法藥物生產中自動和封閉細胞調節的必要性
    • 優勢與挑戰
  • 主要市場促進/抑制因素
  • 最新趨勢和未來趨勢

第4章競爭情況

  • 分析摘要
  • 自動/閉孔調節系統:總體市場情況
    • 單元格調整步驟分析
    • 按單元格類型分析
    • 通過培養方法進行分析
    • 按經營規模分析
    • 主要功能分析
    • 按利用區域分析
    • 分別對法規認證/認證進行分析
    • 最終用戶分析
  • 自動/閉孔調節系統:開發公司的狀況
    • 成立年份分析
    • 按公司規模分析
    • 按提供的支持服務類型進行分析
    • 總公司所在地分析

第5章產品競爭力分析

  • 分析摘要
  • 假設/主要指標
  • 分析方法
  • 產品競爭力分析
    • 自動/閉孔調節系統:用於血液分離
    • 自動/閉孔調節系統:用於分離
    • 自動/閉孔調節系統:增殖
    • 自動/封閉式細胞調節系統:用於細胞回收
    • 自動/密閉電池調節系統:用於填充/整理
    • 自動/密閉電池調節系統:用於冷凍存儲
    • 自動/閉孔調節系統:用於應答

第6章公司簡介

  • 分析摘要
  • Cytiva
    • 公司簡介
    • 產品組合
    • 最新趨勢和未來前景
  • Pall
  • Terumo BCT
  • ThermoGenesis

第7章商業聯盟

  • 分析摘要
  • 商業聯盟(夥伴關係)模型
  • 自動/閉孔調節系統:最近的業務聯盟運動
    • 按年份分析
    • 按業務聯盟類型分析
    • 按治療類型分析
    • 單元格調整步驟分析
    • 按自動/閉孔調節系統類型分析
    • 按優先級分析合作夥伴
    • 最活躍的公司:商業聯盟數量分析
    • 按地區分析

第8章主要製藥公司:自動和密封細胞調節系統領域的舉措

  • 分析摘要
  • 大型製藥公司實施的舉措
    • AbbVie計劃
    • Bristol Myers Squibb計劃
    • Gilead Sciences計劃
    • GlaxoSmithKline計劃
    • Johnson & Johnson計劃
    • Novartis計劃
    • Roche計劃
    • Sanofi計劃
    • Takeda Pharmaceutical計劃
    • 大型製藥公司的計劃:概述

第9章具有潛在聯盟的公司

  • 分析摘要
  • 分析範圍/方法
  • 自動和封閉式細胞調節系統:細胞療法發展的潛在戰略合作夥伴
    • 樹突狀細胞療法
    • 幹細胞療法
    • T細胞療法
    • 自然殺傷細胞療法
  • 封閉式細胞自動調節系統:細胞療法生產的潛在戰略合作夥伴
    • 樹突狀細胞療法
    • 幹細胞療法
    • T細胞療法
    • 自然殺傷細胞療法

第10章案例研究:使用部分/全自動系統的成本/收益分析

  • 分析摘要
  • 手動/半自動/自動細胞調節系統的比較分析
  • Kymriah(R):降低成本的可能性
  • Yescarata(R):降低成本的潛力
  • 通過全自動調整系統降低成本的可能性:各地區的趨勢
  • 結論

第11章市場規模和機會分析

  • 分析摘要
  • 主要假設和分析方法
  • 自動和閉孔調節系統市場:總體分析(2020-2030)
    • 通過調整步驟分解細胞療法
    • 按經營規模細分
    • 最終用戶的細目分類
    • 主要地區的細分

第12章結論

第13章訪談/調查記錄

第14章附錄1:匯總數據

第15章附錄2:公司/組織列表

目錄

Title:
Automated and Closed Cell Therapy Processing Systems Market
By Cell Processing Steps (Apheresis, Separation, Expansion, Harvest, Fill Finish, Cryopreservation and Thawing), Scale of Operations (Preclinical / Clinical and Commercial), End Users (Hospitals / Medical Centers / Clinics / Research Institutes and Commercial Organizations) and Geographical Regions (North America, Europe, Asia Pacific, LATAM and MENA): Industry Trends and Global Forecasts, 2020 - 2030.

Overview:

Advanced therapy medicinal products (ATMPs), such as cell therapies and gene therapies, have revolutionized the healthcare sector. Over the past two decades, more than 30 ATMPs have been approved. Moreover, according to a recent report (published by The Alliance for Regenerative Medicine) , over 1,050 clinical trials are currently being conducted by over 1,000 companies, worldwide, focused on the evaluation of cell and gene therapies. However, despite the numerous advances in this field, there are certain challenges that need to be addressed in order to achieve commercial success. For instance, the current cell therapy manufacturing process is labor-intensive, time consuming and costly. Further, the production of most of these specialized therapeutic products requires manual labor and are typically carried out discretely (open processing) , thereby, rendering the processes difficult to scale-up, with high risk of contamination. Another concern faced by cell and gene therapy manufacturers is batch-to-batch variability, given that even a minor change in the production protocol can affect the quality of the resulting product. Consequently, cell therapies are exorbitantly priced, ranging from USD 300,000 to USD 500,000 per dose.

Experts believe that some of the existing challenges related to cell therapy manufacturing can be addressed through the adoption of automated and closed cell processing systems. These solutions have been demonstrated to be capable of enabling stakeholders to manage various aspects of the cell therapy manufacturing process efficiently, while complying to global regulatory standards. Other benefits of such systems include reduced risk of contamination, optimum utilization of facility and resources, limited in-process variation and consistent product quality. Further, the use of such automated systems enable significant reductions (in the range of 40% to 90%) in labor costs. In recent years, the cost saving potential of these systems, coupled to their ability to streamline and simplify the complex cell therapy processing (from initial cell collection till final formulation) , has effectively captured the interest of several stakeholders engaged in this domain. Given the growing demand for cost-effective, personalized medicine, coupled to the benefits of automated and closed systems, we believe that this niche market is poised to witness significant growth in the foreseen future.

Scope of the Report:

The "Automated and Closed Cell Therapy Processing Systems Market: Focus on Apheresis, Expansion, Harvest, Fill / Finish, Cryopreservation, Thawing, 2020-2030" report features an extensive study of the current market landscape and future opportunities associated with the automated and closed cell therapy processing systems. The study also features a detailed analysis of key drivers and trends related to this evolving domain. Amongst other elements, the report includes:

  • A detailed assessment of the current market landscape, featuring an elaborate list of over 60 automated and closed systems, along with information on the cell therapy processing step for which they are designed (apheresis, separation, expansion, harvest, fill / finish, cryopreservation and thawing) , their key features (traceability, user-friendliness, configurability and scalability, process monitoring, touch-screen user interface, data management, integration with other systems and alert system) , product specifications (length, width, depth, height and weight) , type of cells supported (stem cells and immune cells) , type of cell culture (adherent and suspension) , scale of operation (pre-clinical, clinical and commercial) , application (research and therapeutic), end users (hospitals / medical centers / clinics, research institutes / academic institutes, laboratories, commercial organizations) , key support services offered (product support, technical support, training, installation, qualification / validation, maintenance, regulatory support and others) and regulatory certification / accreditations obtained (GMP / cGMP, GAMP, GCP, GTP / cGTP, IEC standards, ISO standards, 21 CFR Part 11 and other) .
  • An insightful product competitiveness analysis, taking into consideration various relevant parameters, such as supplier power (based on the experience / expertise of the developer in this industry) and portfolio-related parameters, such as number of systems offered, cells supported, type of culture supported, scale of operation, applications, end users, support services offered, regulatory certifications / accreditations obtained and key product specifications.
  • Elaborate profiles of industry players that are currently offering automated and closed cell therapy processing systems, featuring an overview of the company, its financial information (if available), and a detailed description of the system(s) they offer. Each profile also includes a list of recent developments, highlighting the key achievements, partnership activity, and the likely strategies that may be adopted by these players to fuel growth, in the foreseen future.
  • An analysis of the various partnerships pertaining to automated and closed cell therapy processing systems, which have been established since 2016, based on several parameters, such as year of partnership, type of partnership model adopted, type of therapy, type of cell processing step, key automated and closed cell processing systems, partner's focus area, most active players (in terms of number of partnerships signed), and geographical location of collaborators.
  • A review of recent initiatives undertaken by big pharma players in automated and closed cell processing systems domain.

One of the key objectives of the report was to estimate the existing market size and the future growth potential of the automated and closed cell therapy processing systems. Based on various parameters, such as number of cell therapies under development, expected pricing, likely adoption rates, and potential cost saving opportunities from different automated and closed cell processing systems, we have developed informed estimates of the evolution of the market, over the period 2020-2030. In addition, we have provided the likely distribution of the current and forecasted opportunity across [A] different cell therapy processing steps (apheresis, separation, expansion, harvest, fill / finish, cryopreservation and thawing), [B] scale of operations (pre-clinical / clinical and commercial organizations), [C] end users (hospitals / medical centers / clinics, research institutes / academic institutes, laboratories, commercial organizations), and [D] key geographical regions (North America, Europe, Asia-Pacific, Middle East and Latin America). In order to account for the uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios portraying the conservative, base and optimistic tracks of the industry's evolution.

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Peter Molloy (Executive Vice President, Orgenesis) and Shimon Hassin (Chief Technology Officer, Orgenesis)
  • Jean Sebastien Parisse (Commercial Director, Aseptic Technologies)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered:

  • Which are the popular automated and closed systems commonly used for cell therapy processing?
  • Who are the leading industry and non-industry players in this domain?
  • What type of partnership models are commonly adopted by stakeholders in this industry?
  • Which players are likely to be potential partners of automated and closed system providers?
  • What is the current and likely future cost saving opportunities associated with use of automated and closed systems for cell therapy processing?
  • What are the key trends within the automated and closed cell therapy processing systems market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Chapter Outlines:

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the automated and closed cell therapy processing systems market and its likely evolution in the short-mid-term and long term.

Chapter 3 is an introductory chapter that presents a general overview of the cell and advanced therapies domain, along with details on the various types of products. It features a detailed discussion on the key challenges associated with currently adopted cell therapy manufacturing approaches. The chapter also highlights the role of automation in cell therapy manufacturing, providing details on the key advantages and challenges associated with such systems. Further, it features a discussion on the key growth drivers and roadblocks related to the use of such systems, as well as certain trends that the domain is expected to witness in the coming years.

Chapter 4 provides an overview of the automated and closed cell therapy processing systems landscape. It includes information on more than 60 automated and closed systems that are currently being used for processing the cell therapies. It features detailed information on the cell therapy processing step for which they are designed (apheresis, separation, expansion, harvest, fill / finish, cryopreservation and thawing), their key features (traceability, user-friendliness, configurability and scalability, process monitoring, touch-screen user interface, data management, integration with other systems and alert systems), product specifications (length, width, depth, height and weight), type of cells supported (stem cells and immune cells), type of cell culture (adherent and suspension), scale of operation (pre-clinical, clinical and commercial), application (research and therapeutic), end users (hospitals / medical centers / clinics, research institutes / academic institutes, laboratories, commercial organizations), key support services offered (product support, technical support, training, installation, qualification / validation, maintenance, regulatory support and others), regulatory certification / accreditations obtained (GMP / cGMP, GAMP, GCP, GTP / cGTP, IEC standards, ISO standards, 21 CFR Part 11 and other).

Chapter 5 presents a detailed competitiveness analysis of automated and closed cell therapy processing systems based on the supplier power and key product specifications. The analysis was designed to enable stakeholder companies to compare their existing capabilities within and beyond their respective peer groups and identify opportunities to achieve a competitive edge in the industry.

Chapter 6 presents detailed profiles of industry players that are currently offering automated and closed cell therapy processing systems, featuring an overview of the company, its financial information (if available), and a detailed description of the system(s) they offer. Each profile also includes a list of recent developments, highlighting the key achievements, partnership activity, and the likely strategies that may be adopted by these players to fuel growth, in the foreseen future.

Chapter 7 features an elaborate analysis of the various partnerships and collaborations that have been inked amongst players in this domain, during the period 2016-2020. It provides a brief description on the various types of partnership models adopted (including asset purchase agreement, distribution agreement, joint venture, merger / acquisition, product commercialization agreement, product development agreement, product development and commercialization agreement, product evaluation agreement, product integration agreement, product utilization agreement, research agreement and others) by stakeholders in this domain. Further, it includes analyses based on the year of partnership, type of partnership model adopted, type of therapy, type of cell processing step, key automated and closed cell processing systems, partner's focus area, most active players (in terms of number of partnerships signed), and geographical location of collaborators.

Chapter 8 highlights the recent initiatives undertaken by big pharma players in the automated and closed cell therapy processing systems domain.

Chapter 9 features a list of more than 300 cell therapy developers and manufacturers that are anticipated to partner with automated and closed cell therapy processing system providers and have been shortlisted on the basis of parameters, such as developer strength (which takes into account a company's size and its experience in this field), company's pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development), type of culture used (adherent or suspension) and type of technology (automated systems or closed systems).

Chapter 10 presents a case study, highlighting the differences in cost associated with manufacturing of cell therapies using manual, partially automated and bespoke automated and closed systems, across various process operations.

Chapter 11 presents a detailed market forecast analysis, highlighting the likely growth of the automated and closed cell therapy processing systems market till the year 2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] different cell therapy processing steps (apheresis, separation, expansion, harvest, fill / finish, cryopreservation and thawing), [B] scale of operations (pre-clinical / clinical and commercial), [C] end users (hospitals / medical centers / clinics, research institutes / academic institutes, laboratories, commercial organizations), and [D] key geographical regions (North America, Europe, Asia-Pacific, Middle East and Latin America).

Chapter 12 is a collection of interview transcripts of the discussions held with key stakeholders in the industry. We have presented details of interviews held with Peter Molloy (Executive Vice President, Orgenesis) and Shimon Hassin (Chief Technology Officer, Orgenesis), and Jean Sebastien Parisse (Commercial Director, Aseptic Technologies).

Chapter 13 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 14 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 15 is an appendix that provides the list of companies and organizations mentioned in the report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Context and Background
  • 3.2. Cell Therapies
  • 3.3. Cell Therapy Manufacturing
  • 3.4. Key Challenges Associated with Manufacturing Cell Therapies
  • 3.5. Overview of Automated and Closed Cell Processing Systems
    • 3.5.1. Need for Automated and Closed Cell Processing in Cell Therapy Manufacturing
    • 3.5.2. Advantages and Affiliated Challenges
  • 3.6. Key Growth Drivers and Roadblocks
  • 3.7. Recent Developments and Upcoming Trends

4. COMPETITIVE LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Automated and Closed Cell Therapy Processing Systems: Overall Market Landscape
    • 4.2.1. Analysis by Cell Processing Step
    • 4.2.2. Analysis by Types of Cells
    • 4.2.3. Analysis by Type of Culture
    • 4.2.4. Analysis by Scale of Operation
    • 4.2.5. Analysis by Key Features
    • 4.2.6. Analysis by Application Area
    • 4.2.7. Analysis by Regulatory Certifications / Accreditations
    • 4.2.8. Analysis by End User
  • 4.3. Automated and Closed Cell Therapy Processing Systems: Developer Landscape
    • 4.3.1. Analysis by Year of Establishment
    • 4.3.2. Analysis by Company Size
    • 4.3.3. Analysis by Type of Support Service(s) Offered
    • 4.3.4. Analysis by Location of Headquarters

5. PRODUCT COMPETITIVENESS ANALYSIS

  • 5.1. Chapter Overview
  • 5.2. Assumptions / Key Parameters
  • 5.3. Methodology
  • 5.4. Product Competitiveness Analysis
    • 5.4.1. Automated and Closed Cell Processing Systems for Apheresis
    • 5.4.2. Automated and Closed Cell Processing Systems for Separation
    • 5.4.3. Automated and Closed Cell Processing Systems for Expansion
    • 5.4.4. Automated and Closed Cell Processing Systems for Harvest
    • 5.4.5. Automated and Closed Cell Processing Systems for Fill Finish
    • 5.4.6. Automated and Closed Cell Processing Systems for Cryopreservation
    • 5.4.7. Automated and Closed Cell Processing Systems for Thawing

6. COMPANY PROFILES

  • 6.1 Chapter Overview
  • 6.2 Cytiva
    • 6.2.1. Company Overview
    • 6.2.2. Product Portfolio
    • 6.2.3. Recent Developments and Future Outlook
  • 6.3. Pall
    • 6.3.1. Company Overview
    • 6.3.2. Product Portfolio
    • 6.3.3. Recent Developments and Future Outlook
  • 6.4. Terumo BCT
    • 6.4.1. Company Overview
    • 6.4.2. Product Portfolio
    • 6.4.3. Financial Information
    • 6.4.4. Recent Developments and Future Outlook
  • 6.5 ThermoGenesis
    • 6.5.1. Company Overview
    • 6.5.2. Product Portfolio
    • 6.5.3. Financial Information
    • 6.5.4. Recent Developments and Future Outlook

7. PARTNERSHIPS

  • 7.1 Chapter Overview
  • 7.2. Partnership Models
  • 7.3. Automated and Closed Cell Therapy Processing Systems: Recent Partnerships
    • 7.3.1. Analysis by Year of Partnership
    • 7.3.2. Analysis by Type of Partnership
    • 7.3.3. Analysis by Type of Therapy
    • 7.3.4. Analysis by Cell Processing Step
    • 7.3.5. Analysis by Type of Automated and Closed Cell Processing Systems
    • 7.3.6. Analysis by Partner's Focus Area
    • 7.3.7. Most Active Players: Analysis by Number of Partnerships
    • 7.3.8. Geographical Analysis
      • 7.3.8.1. Country-Wise Distribution
      • 7.3.8.2. Intercontinental and Intracontinental Agreements

8. BIG PHARMA INITIATIVES IN AUTOMATED AND CLOSED CELL THERAPY PROCESSING SYSTEMS DOMAIN

  • 8.1. Chapter Overview
  • 8.2. Initiatives Undertaken by Big Pharma Players
    • 8.2.1. Initiatives Undertaken by AbbVie
    • 8.2.2. Initiatives Undertaken by Bristol Myers Squibb
    • 8.2.3. Initiatives Undertaken by Gilead Sciences
    • 8.2.4. Initiatives Undertaken by GlaxoSmithKline
    • 8.2.5. Initiatives Undertaken by Johnson & Johnson
    • 8.2.6. Initiatives Undertaken by Novartis
    • 8.2.7. Initiatives Undertaken by Roche
    • 8.2.8. Initiatives Undertaken by Sanofi
    • 8.2.9. Initiatives Undertaken by Takeda Pharmaceutical
    • 8.2.10. Summary of Big Pharma Initiatives

9. LIKELY PARTNER

  • 9.1. Chapter Overview
  • 9.2. Scope and Methodology
  • 9.3. Automated and Closed Cell Therapy Processing Systems: Potential Strategic Partners for Cell Therapy Development
    • 9.3.1. Dendritic Cell Therapy
    • 9.3.2. Stem Cell Therapy
    • 9.3.3. T-cell Therapy
    • 9.3.4. Natural Killer Cell Therapy
  • 9.4. Automated and Closed Cell Therapy Processing Systems: Potential Strategic Partners for Cell Therapy Manufacturing
    • 9.4.1. Dendritic Cell Therapy
    • 9.4.2. Stem Cell Therapy,
    • 9.4.3. T-cell Therapy
    • 9.4.4. Natural Killer Cell Therapy

10. CASE STUDY: COST BENEFIT ANALYSIS USING PARTIALLY AUTOMATED AND FULLY AUTOMATED SYSTEMS

  • 10.1. Chapter Overview
  • 10.2. Comparative Analysis of Manual, Partially Automated and Fully Automated Cell Processing Systems
  • 10.3. Likely Cost Saving Potential for Kymriah®
  • 10.4. Likely Cost Saving Potential for Yescarata®
  • 10.5. Cost Saving Potential of Fully Automated Processing Systems: Regional Trends
  • 10.6. Concluding Remarks

11. MARKET SIZING AND OPPORTUNITY ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Key Assumptions and Methodology
  • 11.3. Overall Automated and Closed Cell Therapy Processing Systems Market, 2020-2030
    • 11.3.1. Overall Automated and Closed Cell Therapy Processing Systems Market: Distribution by Cell Therapy Processing Step
      • 11.3.1.1. Automated and Closed Cell Therapy Processing Systems Market for Apheresis, 2020-2030
      • 11.3.1.2. Automated and Closed Cell Therapy Processing Systems Market for Separation, 2020-2030
      • 11.3.1.3. Automated and Closed Cell Therapy Processing Systems Market for Expansion, 2020-2030
      • 11.3.1.4. Automated and Closed Cell Therapy Processing Systems Market for Harvest, 2020-2030
      • 11.3.1.5. Automated and Closed Cell Therapy Processing Systems Market for Fill / Finish, 2020-2030
      • 11.3.1.6. Automated and Closed Cell Therapy Processing Systems Market for Cryopreservation, 2020-2030
      • 11.3.1.7. Automated and Closed Cell Therapy Processing Systems Market for Thawing, 2020-2030
    • 11.3.2. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Scale of Operation
      • 11.3.2.1. Automated and Closed Cell Therapy Processing Systems Market for Pre-clinical / Clinical Operations, 2020-2030
      • 11.3.2.2. Automated and Closed Cell Therapy Processing Systems Market for Commercial Operations, 2020-2030
    • 11.3.3. Automated and Closed Cell Therapy Processing Systems Market: Distribution by End User
      • 11.3.3.1. Automated and Closed Cell Therapy Processing Systems Market for Hospitals / Medical Centers / Clinics / Research Institutes / Academic Institutes, 2020-2030
      • 11.3.3.2. Automated and Closed Cell Therapy Processing Systems Market for Cell Therapy Manufacturers / Developers, 2020-2030
    • 11.3.4. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Key Geographic Regions
      • 11.3.4.1. Automated and Closed Cell Therapy Processing Systems Market in North America, 2020-2030
      • 11.3.4.2. Automated and Closed Cell Therapy Processing Systems Market in Europe, 2020-2030
      • 11.3.4.3. Automated and Closed Cell Therapy Processing Systems Market in Asia-Pacific, 2020-2030
      • 11.3.4.4. Automated and Closed Cell Therapy Processing Systems Market in Latin America (LATAM), 2020-2030
      • 11.3.4.5. Automated and Closed Cell Therapy Processing Systems Market in Middle East North America (MENA), 2020-2030

12. CONCLUSION

  • 12.1. Chapter Overview
  • 12.2. Key Takeaways

13. INTERVIEW / SURVEY TRANSCRIPT(S)

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANISTIONS

List Of Figures

  • Figure 3.1. Key Steps Involved in Manufacturing of Cell Therapies
  • Figure 3.2. Key Considerations while Automating Cell Therapy Manufacturing Process
  • Figure 3.3. Role of Automated and Closed Systems across Each Cell Therapy Processing Step
  • Figure 3.4. Advantages offered by Automated and Closed Cell Processing Systems
  • Figure 3.5. Challenges Associated with Automated and Closed Cell Processing Systems
  • Figure 3.6. Growth Drivers and Roadblocks in the Automated and Closed Systems Market
  • Figure 4.1. Automated and Closed Cell Therapy Processing Systems: Distribution by Cell Processing Step
  • Figure 4.2. Automated and Closed Cell Therapy Processing Systems: Distribution by Types of Cells
  • Figure 4.3. Automated and Closed Cell Therapy Processing Systems: Distribution by Type of Culture
  • Figure 4.4. Automated and Closed Cell Therapy Processing Systems: Distribution by Scale of Operation
  • Figure 4.5. Automated and Closed Cell Therapy Processing Systems: Distribution by Key Features
  • Figure 4.6. Automated and Closed Cell Therapy Processing Systems: Distribution by Application Area
  • Figure 4.7. Automated and Closed Cell Therapy Processing Systems: Distribution by Regulatory Certifications / Accreditations
  • Figure 4.8. Automated and Closed Cell Therapy Processing Systems: Distribution by End Users
  • Figure 4.9. Automated and Closed Cell Therapy Processing System Providers: Distribution by Year of Establishment
  • Figure 4.10. Automated and Closed Cell Therapy Processing System Providers: Distribution by Company Size
  • Figure 4.11. Automated and Closed Cell Therapy Processing System Providers: Distribution by Type of Support Services Offered
  • Figure 4.12. Automated and Closed Cell Therapy Processing System Providers: Distribution by Geographical Location
  • Figure 4.13. Automated and Closed Cell Therapy Processing System Providers: Distribution by Geographical Location (Country-Wise)
  • Figure 4.14. Leading Developers: Distribution by Number of Automated and Closed Cell Therapy Processing Systems
  • Figure 5.1. Product Competitiveness Analysis: Automated and Closed Systems for Cell Apheresis
  • Figure 5.2. Product Competitiveness Analysis: Automated and Closed Systems for Cell Separation
  • Figure 5.3. Product Competitiveness Analysis: Automated and Closed Systems for Cell Expansion
  • Figure 5.4. Product Competitiveness Analysis: Automated and Closed Systems for Cell Harvesting
  • Figure 5.5. Product Competitiveness Analysis: Automated and Closed Systems for Fill Finish
  • Figure 5.6. Product Competitiveness Analysis: Automated and Closed Systems for Cryopreservation
  • Figure 5.7. Product Competitiveness Analysis: Automated and Closed Systems for Thawing
  • Figure 6.1. Terumo BCT: Annual Revenues, FY 2016 - FY 2020
  • Figure 6.2. ThermoGenesis: Annual Revenues, FY 2016 - FY 2020
  • Figure 7.1. Recent Partnerships: Cumulative Distribution by Year of Partnership
  • Figure 7.2. Recent Partnerships: Distribution by Type of Partnership Model Adopted
  • Figure 7.3. Recent Partnerships: Year-wise Trend by Type of Partnership Model Adopted
  • Figure 7.4. Recent Partnerships: Distribution by Type of Therapy
  • Figure 7.5. Recent Partnerships: Distribution by Type of Therapy and Type of Partnership Model Adopted
  • Figure 7.6. Recent Partnerships: Distribution by Cell Processing Step
  • Figure 7.7. Recent Partnerships: Distribution by Automated and Closed Cell Processing System
  • Figure 7.8. Recent Partnerships: Distribution by Type of Partner
  • Figure 7.9. Recent Partnerships: Distribution by Type of Cell Processing Step and Developer
  • Figure 7.10. Recent Partnerships: Most Active Players
  • Figure 7.11. Recent Partnerships: Country-Wise Distribution
  • Figure 7.12. Recent Partnerships: Intercontinental and Intracontinental Distribution
  • Figure 8.1. Big Pharma Initiatives Summary
  • Figure 10.1. Cost Saving Analysis: Comparative Analysis of Manual, Partially Automated and Fully Automated Processing Systems, 2020-2030
  • Figure 10.2. Cost Saving Potential of Fully Automated Processing Systems Based on Number of Patients
  • Figure 10.3. Cost Saving Potential of Fully Automated Processing Systems Across Different Regions
  • Figure 11.1. Overall Automated and Closed Cell Therapy Processing Systems Market, 2020-2030 (USD Million)
  • Figure 11.2. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Cell Therapy Processing Step, 2020, 2025 and 2030 (USD Million)
  • Figure 11.3. Automated and Closed Cell Therapy Processing Systems Market: Share of Cell Apheresis Systems, 2020-2030 (USD Million)
  • Figure 11.4. Automated and Closed Cell Therapy Processing Systems Market: Share of Cell Separation Systems, 2020-2030 (USD Million)
  • Figure 11.5. Automated and Closed Cell Therapy Processing Systems Market: Share of Cell Expansion Systems, 2020-2030 (USD Million)
  • Figure 11.6. Automated and Closed Cell Therapy Processing Systems Market: Share of Cell Harvesting Systems, 2020-2030 (USD Million)
  • Figure 11.7. Automated and Closed Cell Therapy Processing Systems Market: Share of Fill Finish Systems, 2020-2030 (USD Million)
  • Figure 11.8. Automated and Closed Cell Therapy Processing Systems Market: Share of Cryopreservation Systems, 2020-2030 (USD Million)
  • Figure 11.9. Automated and Closed Cell Therapy Processing Systems Market: Share of Thawing Systems, 2020-2030 (USD Million)
  • Figure 11.10. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Scale of Operation, 2020, 2025 and 2030 (USD Million)
  • Figure 11.11. Automated and Closed Cell Therapy Processing Systems Market: Share of Preclinical / Clinical Scale Operations, 2020-2030 (USD Million)
  • Figure 11.12. Automated and Closed Cell Therapy Processing Systems Market: Share of Commercial Operations, 2020-2030 (USD Million)
  • Figure 11.13. Automated and Closed Cell Therapy Processing Systems Market: Distribution by End User, 2020, 2025 and 2030 (USD Million)
  • Figure 11.14. Automated and Closed Cell Therapy Processing Systems Market: Share of Hospitals / Medical Centers / Clinics / Research Institutes / Academic Institutes, 2020-2030 (USD Million)
  • Figure 11.16. Automated and Closed Cell Therapy Processing Systems Market: Share of Commercial Organizations, 2020-2030 (USD Million)
  • Figure 11.17. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Key Geographical Regions, 2020, 2025 and 2030 (USD Million)
  • Figure 11.18. Automated and Closed Cell Therapy Processing Systems Market: Share of North America, 2020-2030 (USD Million)
  • Figure 11.19. Automated and Closed Cell Therapy Processing Systems Market: Share of Europe, 2020-2030 (USD Million)
  • Figure 11.20. Automated and Closed Cell Therapy Processing Systems Market: Share of Asia-Pacific, 2020-2030 (USD Million)
  • Figure 11.21. Automated and Closed Cell Therapy Processing Systems Market: Share of LATAM, 2020-2030 (USD Million)
  • Figure 11.22. Automated and Closed Cell Therapy Processing Systems Market: Share of MENA, 2020-2030 (USD Million)

List Of Tables

  • Table 3.1. Cell and Advanced Therapies: Key Applications
  • Table 3.2. Assessment of Key Cell Therapy Manufacturing Steps
  • Table 4.1. List of Automated and Closed Cell Therapy Processing Systems: Information on Cell Processing Step
  • Table 4.2. List of Automated and Closed Cell Therapy Processing Systems: Information on Types of Cells
  • Table 4.3. List of Automated and Closed Cell Therapy Processing Systems: Information on Type of Culture
  • Table 4.4. List of Automated and Closed Cell Therapy Processing Systems: Information on Scale of Operation
  • Table 4.5. List of Automated and Closed Cell Therapy Processing Systems: Information on Key Features
  • Table 4.6. List of Automated and Closed Cell Therapy Processing Systems: Information on Application Area
  • Table 4.7. List of Automated and Closed Cell Therapy Processing Systems: Information on Regulatory Certifications / Accreditations Obtained
  • Table 4.8. List of Automated and Closed Cell Therapy Processing Systems: Information on End Users
  • Table 4.9. List of Automated and Closed Cell Therapy Processing System Providers
  • Table 4.10. List of Automated and Closed Cell Therapy Processing System Providers: Information on Type of Support Service(s) Offered
  • Table 6.1. Cytiva: Key Highlights
  • Table 6.2. Cytiva: Product Portfolio
  • Table 6.3. Pall: Key Highlights
  • Table 6.4. Pall: Product Portfolio
  • Table 6.5. Terumo BCT: Key Highlights
  • Table 6.6. Terumo BCT: Product Portfolio
  • Table 6.7. Terumo BCT: Recent Developments and Future Outlook
  • Table 6.8. ThermoGenesis: Key Highlights
  • Table 6.9. ThermoGenesis: Product Portfolio
  • Table 6.10. ThermoGenesis: Recent Developments and Future Outlook
  • Table 7.1. Automated and Closed Cell Processing Systems: List of Partnerships, 2016-2020
  • Table 8.1. Automated and Closed Cell Processing Systems: List of Big Pharma Players
  • Table 9.1. Likely Partners for Automated and Closed Cell Therapy Processing System Providers: Dendritic Cell Therapy Developers
  • Table 9.2. Likely Partners for Automated and Closed Cell Therapy Processing System Providers: Stem Cell Therapy Developers
  • Table 9.3. Likely Partners for Automated and Closed Cell Therapy Processing System Providers: T-cell Therapy Developers
  • Table 9.4. Likely Partners for Automated and Closed Cell Therapy Processing System Providers: Natural Killer Cell Therapy Developers
  • Table 9.5. Likely Partners for Automated and Closed Cell Therapy Processing System Providers: Dendritic Cell Therapy Manufacturers
  • Table 9.6. Likely Partners for Automated and Closed Cell Therapy Processing System Providers: Stem Cell Therapy Manufacturers
  • Table 9.7. Likely Partners for Automated and Closed Cell Therapy Processing System Providers: T-cell Therapy Manufacturers
  • Table 9.8. Likely Partners for Automated and Closed Cell Therapy Processing System Providers: Natural Killer Cell Therapy Manufacturers
  • Table 10.1. Comparative Analysis of Manual, Partially Automated and Fully Automated Cell Processing Systems, 2020-2030
  • Table 10.2. Cost Saving Potential of Fully Automated Systems
  • Table 14.1. Automated and Closed Cell Therapy Processing Systems: Distribution by Cell Processing Step
  • Table 14.2. Automated and Closed Cell Therapy Processing Systems: Distribution by Types of Cells
  • Table 14.3. Automated and Closed Cell Therapy Processing Systems: Distribution by Type of Culture
  • Table 14.4. Automated and Closed Cell Therapy Processing Systems: Distribution by Scale of Operation
  • Table 14.5. Automated and Closed Cell Therapy Processing Systems: Distribution by Key Features
  • Table 14.6. Automated and Closed Cell Therapy Processing Systems: Distribution by Application Area
  • Table 14.7. Automated and Closed Cell Therapy Processing Systems: Distribution by Regulatory Certifications / Accreditations
  • Table 14.8. Automated and Closed Cell Therapy Processing Systems: Distribution by End Users
  • Table 14.9. Automated and Closed Cell Therapy Processing System Providers: Distribution Year of Establishment
  • Table 14.10. Automated and Closed Cell Therapy Processing System Providers: Distribution by Company Size
  • Table 14.11. Automated and Closed Cell Therapy Processing System Providers: Distribution by Type of Support Services Offered
  • Table 14.12. Automated and Closed Cell Therapy Processing System Providers: Distribution by Geographical Location
  • Table 14.13. Automated and Closed Cell Therapy Processing System Providers: Distribution by Geographical Location (Country-Wise)
  • Table 14.14. Leading Developers: Distribution by Number of Automated and Closed Cell Therapy Processing Systems
  • Table 14.15. Terumo BCT: Annual Revenues, FY 2016-FY 2020
  • Table 14.16. ThermoGenesis: Annual Revenues, FY 2016 - FY 2020
  • Table 14.17. Recent Partnerships: Cumulative Distribution by Year of Partnership
  • Table 14.18. Recent Partnerships: Distribution by Type of Partnership Model Adopted
  • Table 14.19. Recent Partnerships: Year-wise Trend by Type of Partnership Model Adopted
  • Table 14.20. Recent Partnerships: Distribution by Type of Therapy
  • Table 14.21. Recent Partnerships: Distribution by Type of Therapy and Type of Partnership Model Adopted
  • Table 14.22. Recent Partnerships: Distribution by Cell Processing Step
  • Table 14.23. Recent Partnerships: Distribution by Automated and Closed Cell Processing System
  • Table 14.24. Recent Partnerships: Distribution by Type of Partner
  • Table 14.25. Recent Partnerships: Distribution by Type of Cell Processing Step and Developer
  • Table 14.26. Recent Partnerships: Most Active Players
  • Table 14.27. Recent Partnerships: Country-Wise Distribution
  • Table 14.28. Recent Partnerships: Intercontinental and Intracontinental Distribution
  • Table 14.29. Big Pharma Initiatives Summary
  • Table 14.30. Cost Saving Analysis: Comparative Analysis of Manual, Partially Automated and Fully Automated Processing Systems, 2020-2030
  • Table 14.31. Cost Saving Potential of Fully Automated Processing Systems Based on Number of Patients
  • Table 14.32. Cost Saving Potential of Fully Automated Processing Systems Across Different Regions
  • Table 14.33. Overall Automated and Closed Cell Therapy Processing Systems Market, 2020-2030 (USD Million)
  • Table 14.34. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Cell Therapy Processing Step, 2020, 2025 and 2030 (USD Million)
  • Table 14.35. Automated and Closed Cell Therapy Processing Systems Market: Share of Cell Apheresis Systems, 2020-2030 (USD Million)
  • Table 14.36. Automated and Closed Cell Therapy Processing Systems Market: Share of Cell Separation Systems, 2020-2030 (USD Million)
  • Table 14.37. Automated and Closed Cell Therapy Processing Systems Market: Share of Cell Expansion Systems, 2020-2030 (USD Million)
  • Table 14.38. Automated and Closed Cell Therapy Processing Systems Market: Share of Cell Harvesting Systems, 2020-2030 (USD Million)
  • Table 14.39. Automated and Closed Cell Therapy Processing Systems Market: Share of Fill Finish Systems, 2020-2030 (USD Million)
  • Table 14.40. Automated and Closed Cell Therapy Processing Systems Market: Share of Cryopreservation Systems, 2020-2030 (USD Million)
  • Table 14.41. Automated and Closed Cell Therapy Processing Systems Market: Share of Thawing Systems, 2020-2030 (USD Million)
  • Table 14.42. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Scale of Operation, 2020, 2025 and 2030 (USD Million)
  • Table 14.43. Automated and Closed Cell Therapy Processing Systems Market: Share of Preclinical / Clinical Scale Operations, 2020-2030 (USD Million)
  • Table 14.44. Automated and Closed Cell Therapy Processing Systems Market: Share of Commercial Operations, 2020-2030 (USD Million)
  • Table 14.45. Automated and Closed Cell Therapy Processing Systems Market: Distribution by End User, 2020, 2025 and 2030 (USD Million)
  • Table 14.46. Automated and Closed Cell Therapy Processing Systems Market: Share of Hospitals / Medical Centers / Clinics / Research Institutes / Academic Institutes, 2020-2030 (USD Million)
  • Table 14.47. Automated and Closed Cell Therapy Processing Systems Market: Share of Commercial Organizations, 2020-2030 (USD Million)
  • Table 14.48. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Key Geographical Regions, 2020, 2025 and 2030 (USD Million)
  • Table 14.49. Automated and Closed Cell Therapy Processing Systems Market: Share of North America, 2020-2030 (USD Million)
  • Table 14.50. Automated and Closed Cell Therapy Processing Systems Market: Share of Europe, 2020-2030 (USD Million)
  • Table 14.51. Automated and Closed Cell Therapy Processing Systems Market: Share of Asia-Pacific, 2020-2030 (USD Million)
  • Table 14.52. Automated and Closed Cell Therapy Processing Systems Market: Share of LATAM, 2020-2030 (USD Million)
  • Table 14.53. Automated and Closed Cell Therapy Processing Systems Market: Share of MENA, 2020-2030 (USD Million)

List of Companies

The following companies / institutes / government bodies and organizations have been mentioned in the report.

  • 1. 3P Biopharmaceuticals
  • 2. A*STAR's Institute of Molecular and Cell Biology
  • 3. AbbVie
  • 4. Accellix
  • 5. Acer Therapeutics
  • 6. Achilles Therapeutics
  • 7. Activartis Biotech
  • 8. Adaptimmune
  • 9. Adicet Bio
  • 10. Aduro Biotech
  • 11. Adva Biotechnology
  • 12. Advent Bioservices
  • 13. AgenTus Therapeutics
  • 14. Aglaris
  • 15. AK (Suzhou) Biomedical
  • 16. Aldagen
  • 17. Allele Biotechnology & Pharmaceuticals
  • 18. Allergan
  • 19. Allife Medical Science and Technology
  • 20. Allogene Therapeutics
  • 21. Altor BioScience
  • 22. AmerCare
  • 23. Amgen
  • 24. Amphera
  • 25. Anhui Kedgene Biotechnology
  • 26. ANI Pharmaceuticals
  • 27. Anterogen
  • 28. apceth Biopharma
  • 29. Araymondlife
  • 30. ARBELE
  • 31. Argos Therapeutics
  • 32. Asahi Glass Company
  • 33. Aseptic Technologies
  • 34. Astellas Pharma
  • 35. Asterias Biotherapeutics
  • 36. Astraveus
  • 37. AstraZeneca
  • 38. Asymptote
  • 39. Atara Biotherapeutics
  • 40. Athersys
  • 41. Atlantic Bio GMP
  • 42. ATLATL Innovation Cluster
  • 43. Atreca
  • 44. Aurora Biopharma
  • 45. Autolus
  • 46. AVAX Technologies
  • 47. Basic Pharma
  • 48. Batavia Bioservices
  • 49. Bavarian Nordic
  • 50. Baxalta
  • 51. Baxter
  • 52. Bayer
  • 53. Beijing Biohealthcare Biotechnology
  • 54. Beijing Doing Biomedical
  • 55. Beijing Immunochina Medical Science & Technology
  • 56. Beijing Sanwater Biological Technology
  • 57. Beijing Tricision Biotherapeutics
  • 58. Beike Biotechnology
  • 59. Bellicum Pharmaceuticals
  • 60. Bio Elpida
  • 61. BioAtla
  • 62. BioCardia
  • 63. Biogen
  • 64. Bioinova
  • 65. BioNTech Innovative Manufacturing Services
  • 66. Bio-Process Systems Alliance
  • 67. BioRestorative Therapies
  • 68. Biosafe
  • 69. Biotec Services International
  • 70. Bio-Techne
  • 71. bluebird bio
  • 72. Boehringer Ingelheim
  • 73. Bone Therapeutics
  • 74. BrainStorm Cell Therapeutics
  • 75. Brammer Bio
  • 76. Bristol Myers Squibb
  • 77. BTI
  • 78. Caladrius Biosciences
  • 79. CANCER-ID
  • 80. Capricor Therapeutics
  • 81. Captain T Cell
  • 82. CardioCell
  • 83. Carina Biotech
  • 84. CARsgen Therapeutics
  • 85. CAR-T (Shanghai) Biotechnology
  • 86. Cartherics
  • 87. Celgene
  • 88. Celixir
  • 89. Cell and Gene Therapy Catapult
  • 90. Cell Biotech
  • 91. Cell Genesys
  • 92. Cell Tech Pharmed
  • 93. Cell Therapies
  • 94. Cellectis
  • 95. CELLforCURE
  • 96. CellGenix
  • 97. Cellin Technologies
  • 98. Cellmed
  • 99. CellPraxis
  • 100. CellProtect Nordic Pharmaceuticals
  • 101. CellProthera
  • 102. Cellular Biomedicine Group
  • 103. Cellular Therapeutics
  • 104. Celularity
  • 105. Celyad
  • 106. Centre for Commercialization of Regenerative Medicine
  • 107. Chengdu MedGenCell
  • 108. CiMaas
  • 109. Cognate BioServices
  • 110. Cook MyoSite
  • 111. Cord Blood Registry
  • 112. Cordlife
  • 113. Corestem
  • 114. CRISPR Therapeutics
  • 115. CRMI
  • 116. Cryosite
  • 117. Cytiva
  • 118. Cytopeutics
  • 119. Cytori Therapeutics
  • 120. Cytosen Therapeutics
  • 121. Cytovac
  • 122. CyTuVax
  • 123. Daiichi Sankyo
  • 124. Daikyo Seiko
  • 125. Danaher
  • 126. DanDrit Biotech
  • 127. DCPrime
  • 128. Delta-Vir
  • 129. DEMCON
  • 130. Dendreon
  • 131. DiscGenics
  • 132. Draper
  • 133. Eli Lilly
  • 134. Endocyte
  • 135. Esco Aster
  • 136. Esco VacciXcell
  • 137. Eureka Therapeutics
  • 138. Eutilex
  • 139. Ever Union Biotechnology
  • 140. eXmoor Pharma Concepts
  • 141. EXUMA Biotechnology
  • 142. Fate Therapeutics
  • 143. Ferrer Internacional
  • 144. FIB Hospital Infantil Universitario Niño Jesús
  • 145. Fibrocell Technologies
  • 146. Five Prime Therapeutics
  • 147. Flaskworks
  • 148. FloDesign Sonics
  • 149. Formula Pharmaceuticals
  • 150. Fortress Biotech
  • 151. Fred Hutchinson Cancer Research Center
  • 152. Freeline
  • 153. Fresenius Kabi
  • 154. FUJIFILM Cellular Dynamics
  • 155. FUJIFILM Diosynth Biotechnologies
  • 156. Gadeta
  • 157. Gamida Cell
  • 158. GC Cell
  • 159. G-Con Manufacturing
  • 160. GE Healthcare
  • 161. GE Medical Systems Trade & Development (Shanghai)
  • 162. Genentech
  • 163. Genzyme
  • 164. GigaGen
  • 165. Gilead Sciences
  • 166. GlaxoSmithKline
  • 167. Global Cell Med
  • 168. Glycostem Therapeutics
  • 169. GPB Scientific
  • 170. Gracell Biotechnologies
  • 171. Gradalis
  • 172. Green Cross
  • 173. GRI Bio
  • 174. Guangzhou Trinomab Biotech
  • 175. Haemonetics
  • 176. Heat Biologics
  • 177. Hebei Senlang Biotechnology
  • 178. Hemostemix
  • 179. HengRui YuanZheng Bio-Technology
  • 180. Histocell
  • 181. Histogenics
  • 182. Hitachi Chemical Advanced Therapeutics Solutions
  • 183. Holostem Terapieavanzate
  • 184. Human Life CORD Japan
  • 185. Hunan Zhaotai Yongren Biotech
  • 186. iCarTAB BioMed
  • 187. iCell Gene Therapeutics
  • 188. Immatics
  • 189. Immune Therapeutics
  • 190. Immunicum
  • 191. ImmunoCellular Therapeutics
  • 192. Immunocore
  • 193. Immunovative Therapies
  • 194. IncoCell Tianjin
  • 195. Incysus
  • 196. Innovative Cellular Therapeutics
  • 197. Inovio Pharmaceuticals
  • 198. inRegen
  • 199. Intellia Therapeutics
  • 200. Intrexon
  • 201. Invetech
  • 202. Iovance Biotherapeutics
  • 203. ISTO Technologies
  • 204. Ivy Life Sciences
  • 205. Janssen
  • 206. Japan Tissue Engineering (J-TEC)
  • 207. Johns Hopkins University
  • 208. Johnson & Johnson
  • 209. Juno Therapeutics
  • 210. JW Biotechnology
  • 211. JW CreaGene
  • 212. KangStem Biotech
  • 213. Kawasaki Heavy Industries
  • 214. KBI Biopharma
  • 215. Kiromic
  • 216. Kite Pharma
  • 217. Konkuk University
  • 218. kSep Systems
  • 219. Kuur Therapeutics
  • 220. Legend Biotech
  • 221. Leucid Bio
  • 222. Lifecells
  • 223. Lion TCR
  • 224. Living Pharma
  • 225. Longeveron
  • 226. Lonza
  • 227. Lorem Cytori
  • 228. Lorem Vascular
  • 229. Marino Biotechnology
  • 230. Marker Therapeutics
  • 231. MaSTherCell
  • 232. Max Planck Institute for Dynamics of Complex Technical Systems
  • 233. MaxCyte
  • 234. MedCision
  • 235. Medeor Therapeutics
  • 236. Medigene
  • 237. MEDINET
  • 238. MEDIPOST
  • 239. MedVax Technologies
  • 240. Merck
  • 241. Merck Serono
  • 242. Mesoblast
  • 243. MicrofluidX
  • 244. Miltenyi Biotec
  • 245. Minovia Therapeutics
  • 246. MolecuVax
  • 247. MolMed
  • 248. Moraga Biotechnology
  • 249. Multimmune
  • 250. Mustang Bio
  • 251. NantKwest
  • 252. Neopharm
  • 253. NewLink Genetics
  • 254. Nikon CeLL innovation
  • 255. Nkarta
  • 256. Noga Therapeutics
  • 257. Nohla Therapeutics
  • 258. Noile-Immune Biotech
  • 259. Northern Therapeutics
  • 260. Northwest Biotherapeutics
  • 261. Novadip Biosciences
  • 262. Novartis
  • 263. NovaRx
  • 264. Novella Clinical
  • 265. Novo Nordisk
  • 266. Octane Biotech
  • 267. OhioHealth
  • 268. OiDE BetaRevive
  • 269. Ompi
  • 270. Oncobiomed
  • 271. Opexa Therapeutics
  • 272. Orchard Therapeutics
  • 273. Orgenesis
  • 274. Ori Biotech
  • 275. Osiris Therapeutics
  • 276. OSPIN
  • 277. Oxford BioMedica
  • 278. Oxford MEStar
  • 279. Pall Corporation
  • 280. Parker Institute for Cancer Immunotherapy
  • 281. PDC*line Pharma
  • 282. PersonGen BioTherapeutics
  • 283. Pfizer
  • 284. PharmaBio
  • 285. PharmaCell
  • 286. Pharmicell
  • 287. Pinze Lifetechnology
  • 288. Pique Therapeutics
  • 289. Pluristem Therapeutics
  • 290. Poseida Therapeutics
  • 291. Praxis Pharmaceutical
  • 292. Precision BioSciences
  • 293. Pregene ShenZhen Biotechnology
  • 294. Immutep
  • 295. Promethera Biosciences
  • 296. Regeneris Medical
  • 297. Regeneron
  • 298. Regeneus
  • 299. ReNeuron
  • 300. RHEACELL
  • 301. Roche
  • 302. Roslin Cells
  • 303. Sangamo Therapeutics
  • 304. Sanofi
  • 305. Saronic Biotechnology
  • 306. Sartorius
  • 307. Sartorius Stedim Biotech
  • 308. SCHOTT
  • 309. Scinogy
  • 310. Scinus Cell Expansion
  • 311. Sclnow Biotechnology
  • 312. Seattle Genetics
  • 313. Seneca Biopharma
  • 314. Sentien Biotechnologies
  • 315. Servier
  • 316. Shanghai Bioray Laboratory
  • 317. Shanghai GeneChem
  • 318. Shanghai Houchao Biotechnology
  • 319. Shanghai iCELL Biotechnology
  • 320. Shanghai Longyao Biotechnology
  • 321. Shanghai Unicar-Therapy Bio-medicine Technology
  • 322. Sheba Medical Center
  • 323. Shenzhen BinDeBio
  • 324. Shenzhen Hornetcorn Biotechnology
  • 325. Shibuya
  • 326. Shionogi
  • 327. Shreedhar Instruments
  • 328. Singota Solutions
  • 329. Sinobioway Cell Therapy
  • 330. SMT Bio
  • 331. Sorrento Therapeutics
  • 332. SOTIO
  • 333. Southwest Research Institute
  • 334. SQZ Biotech
  • 335. Stafa Cellular Therapy
  • 336. Stanford School of Medicine
  • 337. Stem Cell Arabia
  • 338. STEMCELL Technologies
  • 339. Stemedica Cell Technologies
  • 340. Stempeutics Research
  • 341. Super-T Cell Cancer Company
  • 342. Surface Oncology
  • 343. Tactiva Therapeutics
  • 344. Taiwan Bio Therapeutics
  • 345. Takara Bio
  • 346. Takeda Pharmaceuticals
  • 347. TapImmune
  • 348. Targazyme
  • 349. TC BioPharm
  • 350. TCR2 Therapeutics
  • 351. Tella
  • 352. Terumo BCT
  • 353. Tessa Therapeutics
  • 354. Teva Pharmaceutical Industries
  • 355. TheraCell Advanced Biotechnology
  • 356. Thermo Fisher Scientific
  • 357. ThermoGenesis
  • 358. Tianhe Stem Cell Biotechnologies
  • 359. TiGenix
  • 360. TILT Biotherapeutics
  • 361. Tissue Genesis
  • 362. Tmunity Therapeutics
  • 363. TNK Therapeutics
  • 364. TotipotentRX
  • 365. TRACT Therapeutics
  • 366. TrakCel
  • 367. TransCure BioServices
  • 368. Triumvira Immunologics
  • 369. TVAX Biomedical
  • 370. Shanghai Unicar Therapy Bio medicine Technology
  • 371. Universal Cells
  • 372. University of California, Davis
  • 373. University Of North Carolina Lineberger Comprehensive Cancer Center
  • 374. Unum Therapeutics
  • 375. US Stem Cell
  • 376. Vaccinogen
  • 377. Vanrx Pharmasystems
  • 378. Vericel
  • 379. ViroMed
  • 380. Viscofan BioEngineering
  • 381. VivaBioCell
  • 382. Volta Therapeutics
  • 383. Waisman Biomanufacturing
  • 384. WiSP Wissenschaftlicher Service Pharma
  • 385. Wuhan Sian Medical Technology
  • 386. WuXi AppTec
  • 387. Xcelthera
  • 388. Xellbiogene
  • 389. XEME Biopharma
  • 390. Yposkesi
  • 391. Zelluna Immunotherapy
  • 392. Zenith Technologies
  • 393. Zimmer Biomet
  • 394. Ziopharm Oncology